Open Access
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, Janice P Dutcher
DOI: 10.1136/jim-2020-001650 Published 4 February 2021
Joseph I Clark
1Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA
Brendan Curti
2Earle A. Chiles Research Institute, Providence Medical Center, Portland, Oregon, USA
Elizabeth J Davis
3Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Howard Kaufman
4Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
Asim Amin
5Medicine, Levine Cancer Institute, Charlotte, North Carolina, USA
Ajjai Alva
6Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA
Theodore F Logan
7Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA
Ralph Hauke
8Medicine, Nebraska Cancer Specialists, Omaha, Nebraska, USA
Gerald P Miletello
9Medicine, Hematology/Oncology Clinic, Baton Rouge, Louisiana, USA
Ulka Vaishampayan
10Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
Douglas B Johnson
3Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Richard L White
5Medicine, Levine Cancer Institute, Charlotte, North Carolina, USA
Peter H Wiernik
11Medicine, New York Medical College, Valhalla, New York, USA
Janice P Dutcher
11Medicine, New York Medical College, Valhalla, New York, USA
No eLetters have been published for this article.
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, Janice P Dutcher
Journal of Investigative Medicine Feb 2021, jim-2020-001650; DOI: 10.1136/jim-2020-001650
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, Janice P Dutcher
Journal of Investigative Medicine Feb 2021, jim-2020-001650; DOI: 10.1136/jim-2020-001650
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, Janice P Dutcher
Journal of Investigative Medicine Feb 2021, jim-2020-001650; DOI: 10.1136/jim-2020-001650